Released on: October 7, 2008, 1:44 am

Press Release Author: FranTech Asia

Industry: Biotech

Press Release Summary: FranTech Asia / FranMedics Division and Munogenics, Inc.enter
into a Global Marketing Agreement to license Munogenics developments, test,novel
biological methods for testing and preventing malignant diseases in humans delivery
field to advance clinical trials.


Press Release Body: AHMEDABAD, Gujarat, India, -- October 6, 2008 -- FranTech Asia
licensing Munogenics, Inc. in collaboration with a research team Led by
Dr. Zheng Cui, MD/PhD, at Wake Forest University Health Sciences("WFUHS") and will
license US-based Munogenics, Inc. worldwide and today announced that they have
entered a Global Marketing Agreement with FranTech Asia, FranTech Switzerland,
Global FranTech Group and
FranTech's / FranMedics division a license agreement for Munogenics "GIFT" and "CKA"
cellline technology testing to be licensed into 220
countries.


Under the terms of the FranTech / FranMedics Global Marketing Agreement, Munogenics
will use Wake Forest University Health Sciences,
Medical Center ("WFUHS") new cancer treatments technology for research in the field
of adenovirus-based gene delivery for cancer treatment.


Munogenics has also obtained an option for a non-exclusive commercial license to use
"GIFT" and "CKA" new cancer treatment cells process to
manufacture and sell Munogenics future treatment products in the field of gene
delivery for cancer treatment. Munogenics will receive upfront
and annual payments for the research license marketed by FranTech / FranMedics
Division into 220 countries.

If the Munogenics research license is converted into a commercial license,
Munogenics will receive additional annual payments and royalties on future sales of
'GIFT" and "CKA"-derived products. Further financial details were not disclosed.


"This FranTech /FranMedics licensing into 220 countries represents an important
building block in our Munogenics program to move Munogenics
cancer treatments into clinical trials worldwide.

We perceive the Munogenics to be the best available for delivering the "GIFT" and
"CKA" new cancer treatments," said Dr.Beau Raines, President
& CEO of Munogenics.

"We expect to sign the first Munogenics licensee’s for "GIFT"(GRANULOCYTE INFUSION
THERAPY) treatment process, and the "CKA" (CANCER KILLING ACTIVITY) test license in
2009. Since that time "GIFT" and "CKA will become the new 'industry standard' in the
area of adenovirus-based gene delivery.

Currently, no "GIFT" or "CKA"-based products are in clinical trials or in
production," commented Philip Nadeau, Global FranTech Group's Chairman
and CEO. "As worldwide interest in "GIFT" and "CKA" gene delivery expands, we
believe new opportunities for future licensing agreements
will further strengthen Munogenics's licensing value to this industry."


In collaboration with a research team led by Dr. Zheng Cui, MD/ PhD and Professor
Mak Willingham, MD, at Wake Forest University Health Sciences
("WFUHS") School of Medicine, Medical Center, Munogenics plans to commercialize a
new cancer treatment. Termed the "GIFT" (Granulocyte
InFusion Therapy) process, and "CKA" Cancer Killing Activity" test with the goal of
eliminating various types of cancer in humans.

Munogenics, Inc. is committed to improving public health through the development of
"GIFT" and "CKA" process and future development of advanced vaccines and antibodies
that prevent or treat infectious diseases.

Munogenics, Inc will license development of vaccines and licenses its
COMMERCIALIZING A NEW CANCER TREATMENT ("GIFT" and "CKA") process and
production technology to Life Science companies in the pharmaceutical and
biotechnology industry in 220 countries. The company's licensees
include for its future cancer treatments "GIFT" and it's "CKA" CANCER vaccine,
Munogenics "GIFT" and "CKA", licenses marketed through FranTech and FranMedics
division, "A Worldwide Company”.


The Munogenics company has an alliance with "CKA" Biologics China to produce
monoclonal antibodies and recombinant proteins. Munogenics has
partnered with the US Wake Forest University Health Sciences ("WFUHS") for the
development of an "GIFT" and "CKA" future vaccine. Munogenics is
also be developing a human vaccine based on ("GIFT' and "CKA") studies. Munogenics,
Inc. is headquartered in Austin, Texas, and is soon will be listed on the Euronext
and NASDAQ stock exchanges (new ticker symbol may be MGIL).

For more information visit: http://www.FranTechAsia.com

About Munogenics, Inc.
Munogenics Inc. develops,test, and licenses novel biological methods for treating
and preventing malignant disease in humans. The company has a
propriety revolutionary platform for cancer treatment that shows exceptional
efficacy and minimal side effect in treating cancers.
Munogenics is developing a biotechnology company specialising in the discovery and
development of immunotherapeutics aimed at the treatment
and eradication of cancer, and therapies for infectious diseases, autoimmune
disorders and transplant tissue rejection.

Munogenics's will have a lead treatment process and product, the "GIFT"(GRANULOCYTE
INFUSION THERAPY) processes and the "CKA" (CANCER KILLING
ACTIVITY) test with the goal of eliminating various types of cancer in humans and
producing a Munogenics cancer vaccine that will be an
immunotherapy for many forms of cancer, including cancers of the lung,liver, kidney,
head and neck, breast, prostate, and cervix, as well as
colorectal cancer and melanoma.

These cancers are characterized by defects in the cellular, antigen presentation
pathway, which results in the cancers becoming invisible to
the immune system.

Munogenics future vaccine will increases the activity of the antigen presentation
pathway thus providing sufficient information to the immune
system to cause rejection and elimination of cancer from the body.

FranTech Asia / FranMedics Divsion will License Munogenics, Inc., developments, test
and licenses novel biological methods for treating and
preventing malignant diseases in humans.The Company has a worldwide proprietary
revolutionary platform for cancer treatment that shows
exceptional efficacy and minimal side effects in treating cancers for worldwide
licensing into 220 countries by FranTech / FranMedics division.

In collaboration with a world class research team led by Dr. Zheng Cui, MD/PhD, at
Wake Forest University Health Sciences, ("WFUHS"),
Munogenics plans to commercialize a new cancer treatment, termed the "GIFT"
(Granulocyte InFusion Therapy) process, and the "CKA" (Cancer Killing Activity) test
with the goal of eliminating various types of cancers in humans.

A UNQUE APPROACH - GIFT and CKA
The GIFT treatment process, discovered by Professor CUI, MD/PhD and Professor Mark
Willingham, MD, has revealed during initial and
subsequent testing that;

* Certain humans posses a genetically defined and inheritable activity in their
granulocytes to destroy a wide range of highly lethal cancers.

* This therapeutic activity can be transfused from cancer resistant donors to
cancer-susceptible recipients for highly effective cancer treatment with minimal
side effect.

Additionally, Munogencis also plans to license and commercialize a proprietary human
test measuring CKA to determine an individual's susceptibility, or resistance to
various types of cancers so that the risk for cancer can be managed or prevented.

The CKA test will be used to identify potential donors for the GIFT cancers
treatment process. Furthermore, the CKA test will measure
granulocyte supplies in the following for humans:

*Selection for donors with high CKA (Cancer Therapy)

* Monitoring CKA in healthy population for cancer risk management

(Prevention of Cancer)
* Monitoring CKA in cryo-stored cells (Aging Prevention)

CURRENT CANCER TREATMENTS
Current cancer treatments method revolve around the principal of using outside
factors (surgery, radiation, cytotoxic chemotherapy) to seek
out and destroy cancerous cells All of these treatments cause significant damage to
healthy cells surrounding the cancer, causing dangerous side effects.

Conventional pathways from laboratory discoveries to human trials using man-made
cancer drug development usually require a lengthy process of
testing efficacy and safety and initial design and development.

The CKA-based approach of detecting and the GIFT therapeutic process for eliminating
cancer relies on selecting specifically ready therapeutic
reagents (human granulocytes) for direct use without any manipulation.

The collection and transfusion process for human granulocytes has previously been
approved by the FDA for human clinical use for other clinical indications, such as
infections associated with neutropenia.

The CKA testing approach has been previously validated using a sampling of over
hundreds of human subjects.

A volunteer population eligible for granulocyte donation for testing the GIFT
treatment process has been identified.

GIFT consists of 4 major novel components which distinguish it from other cancer
immuno therapies:

* Collects donor cells from correct cancer-resistant humans based on screening for
high CKA, but not from random donors.

* Collects and uses the specific types of donor cells which contain the highest CKA
and minimizes potential side-effects

* Collects the donor cells at the precisely most effective time, since
CKA is influenced profoundly by seasonality.

* Collects sufficient number of granulocytes to achieve critical
therapeutic doses

Munogenics Inc., is headquartered in Austin, Texas, USA and soon with licensed
operations in worldwide in 220 markets.

For more information visit:

http://www.FranTechUSA.com

This press release contains forward-looking statements that involve inherent risks
and uncertainties. We have identified certain important factors that may cause
actual results to differ materially from those contained in such forward-looking
statements.


For information relating to these factors please refer to our Form 20-F, as filed
with the U.S. Securities and Exchange Commission on April
18, 2003, and the section entitled "Risk Factors". The company prepares its
financial statements under generally accepted accounting principles
in the United States (US GAAP).

Distributed by FranTech USA on behalf of Global FranTech Group "A Worldwide Company"


Contact Information:
FranTech Asia International Licensing Ltd. Ahmedabad, Gujarat, India
Shanker Damodaran, President
Tel : + 0091-932-706-7935
Fax : + 805-643-4386
E-mail :President@FranTechAsia.com
Copyright © 2008 Global FranTech Group. All rights reserved.

A FranTech Universal Business Media Company.
- FranMedics Division -Released October - 2008

www.FranTechWTC-3G.com


Web Site: http://www.FranTechAsia.com

Contact Details: FranTech Asia International Licensing Ltd. Ahmedabad, Gujarat, India
Tel : + 0091-932-706-7935
Fax : + 805-643-4386
E-mail:President@FranTechAsia.com